Tyra Biosciences Stock Net Income
| TYRA Stock | USD 31.08 0.32 1.02% |
As of the 29th of January, Tyra Biosciences has the Semi Deviation of 1.59, risk adjusted performance of 0.219, and Coefficient Of Variation of 349.16. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tyra Biosciences, as well as the relationship between them.
Tyra Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Tyra Biosciences' valuation are provided below:We have found one hundred twenty available fundamental trend indicators for Tyra Biosciences, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Tyra Biosciences current market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. The current year's Enterprise Value is expected to grow to about 670.6 M, whereas Market Cap is forecasted to decline to about 452.5 M. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -77.8 M | -73.9 M | |
| Net Loss | -49.8 M | -47.3 M | |
| Net Loss | -77.8 M | -73.9 M | |
| Net Loss | (1.74) | (1.83) | |
| Net Income Per E B T | 1.15 | 1.10 |
Tyra | Net Income | Build AI portfolio with Tyra Stock |
Latest Tyra Biosciences' Net Income Growth Pattern
Below is the plot of the Net Income of Tyra Biosciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Tyra Biosciences financial statement analysis. It represents the amount of money remaining after all of Tyra Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Tyra Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tyra Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (86.48 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Tyra Net Income Regression Statistics
| Arithmetic Mean | (25,596,891) | |
| Coefficient Of Variation | (124.52) | |
| Mean Deviation | 27,255,507 | |
| Median | (4,058,000) | |
| Standard Deviation | 31,874,140 | |
| Sample Variance | 1016T | |
| Range | 82.4M | |
| R-Value | (0.84) | |
| Mean Square Error | 319.3T | |
| R-Squared | 0.71 | |
| Significance | 0.000025 | |
| Slope | (5,301,052) | |
| Total Sum of Squares | 16255.4T |
Tyra Net Income History
Other Fundumenentals of Tyra Biosciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Tyra Biosciences Net Income component correlations
Tyra Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Tyra Biosciences is extremely important. It helps to project a fair market value of Tyra Stock properly, considering its historical fundamentals such as Net Income. Since Tyra Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tyra Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tyra Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tyra Biosciences. If investors know Tyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Tyra Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Tyra Biosciences requires distinguishing between market price and book value, where the latter reflects Tyra's accounting equity. The concept of intrinsic value—what Tyra Biosciences' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Tyra Biosciences' price substantially above or below its fundamental value.
Please note, there is a significant difference between Tyra Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tyra Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Tyra Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Tyra Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Tyra Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Tyra Biosciences.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Tyra Biosciences on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Tyra Biosciences or generate 0.0% return on investment in Tyra Biosciences over 90 days. Tyra Biosciences is related to or competes with Rezolute, Savara, Geron, Prime Medicine, Day One, Kura Oncology, and Maravai Lifesciences. Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor... More
Tyra Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Tyra Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Tyra Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.49 | |||
| Information Ratio | 0.2698 | |||
| Maximum Drawdown | 34.11 | |||
| Value At Risk | (2.98) | |||
| Potential Upside | 6.05 |
Tyra Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tyra Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Tyra Biosciences' standard deviation. In reality, there are many statistical measures that can use Tyra Biosciences historical prices to predict the future Tyra Biosciences' volatility.| Risk Adjusted Performance | 0.219 | |||
| Jensen Alpha | 1.32 | |||
| Total Risk Alpha | 0.8857 | |||
| Sortino Ratio | 0.4902 | |||
| Treynor Ratio | (2.22) |
Tyra Biosciences January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.219 | |||
| Market Risk Adjusted Performance | (2.21) | |||
| Mean Deviation | 2.72 | |||
| Semi Deviation | 1.59 | |||
| Downside Deviation | 2.49 | |||
| Coefficient Of Variation | 349.16 | |||
| Standard Deviation | 4.52 | |||
| Variance | 20.43 | |||
| Information Ratio | 0.2698 | |||
| Jensen Alpha | 1.32 | |||
| Total Risk Alpha | 0.8857 | |||
| Sortino Ratio | 0.4902 | |||
| Treynor Ratio | (2.22) | |||
| Maximum Drawdown | 34.11 | |||
| Value At Risk | (2.98) | |||
| Potential Upside | 6.05 | |||
| Downside Variance | 6.19 | |||
| Semi Variance | 2.53 | |||
| Expected Short fall | (3.31) | |||
| Skewness | 3.02 | |||
| Kurtosis | 14.7 |
Tyra Biosciences Backtested Returns
Tyra Biosciences is not too volatile given 3 months investment horizon. Tyra Biosciences owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.26, which indicates the firm had a 0.26 % return per unit of risk over the last 3 months. We were able to interpolate data for twenty-seven different technical indicators, which can help you to evaluate if expected returns of 1.21% are justified by taking the suggested risk. Use Tyra Biosciences Risk Adjusted Performance of 0.219, semi deviation of 1.59, and Coefficient Of Variation of 349.16 to evaluate company specific risk that cannot be diversified away. Tyra Biosciences holds a performance score of 20 on a scale of zero to a hundred. The entity has a beta of -0.58, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Tyra Biosciences are expected to decrease at a much lower rate. During the bear market, Tyra Biosciences is likely to outperform the market. Use Tyra Biosciences expected short fall, and the relationship between the value at risk and day median price , to analyze future returns on Tyra Biosciences.
Auto-correlation | 0.89 |
Very good predictability
Tyra Biosciences has very good predictability. Overlapping area represents the amount of predictability between Tyra Biosciences time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Tyra Biosciences price movement. The serial correlation of 0.89 indicates that approximately 89.0% of current Tyra Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.89 | |
| Spearman Rank Test | 0.88 | |
| Residual Average | 0.0 | |
| Price Variance | 7.31 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Tyra Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Tyra Biosciences reported net income of (86.48 Million). This is 125.34% lower than that of the Biotechnology sector and 223.46% lower than that of the Health Care industry. The net income for all United States stocks is 115.15% higher than that of the company.
Tyra Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tyra Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tyra Biosciences could also be used in its relative valuation, which is a method of valuing Tyra Biosciences by comparing valuation metrics of similar companies.Tyra Biosciences is currently under evaluation in net income category among its peers.
Tyra Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tyra Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tyra Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Tyra Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Tyra Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Tyra Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Tyra Biosciences' value.| Shares | Vanguard Group Inc | 2025-06-30 | 1.4 M | Farallon Capital Management, L.l.c. | 2025-06-30 | 1.1 M | 5am Venture Management, Llc | 2025-06-30 | 939.3 K | Sio Capital Management, Llc | 2025-06-30 | 810.3 K | Orbimed Advisors, Llc | 2025-06-30 | 804.6 K | Balyasny Asset Management Llc | 2025-06-30 | 583.4 K | Geode Capital Management, Llc | 2025-06-30 | 567.1 K | Marshall Wace Asset Management Ltd | 2025-06-30 | 428.1 K | State Street Corp | 2025-06-30 | 419 K | Ra Capital Management, Llc | 2025-06-30 | 12.2 M | Alta Partners Management Company, L.p. | 2025-06-30 | 4.1 M |
Tyra Fundamentals
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 1.41 B | ||||
| Shares Outstanding | 53.37 M | ||||
| Shares Owned By Insiders | 3.16 % | ||||
| Shares Owned By Institutions | 96.84 % | ||||
| Number Of Shares Shorted | 5.07 M | ||||
| Price To Earning | (3.33) X | ||||
| Price To Book | 5.97 X | ||||
| EBITDA | (103.66 M) | ||||
| Net Income | (86.48 M) | ||||
| Cash And Equivalents | 275.11 M | ||||
| Cash Per Share | 6.61 X | ||||
| Total Debt | 6.22 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 50.83 X | ||||
| Book Value Per Share | 5.26 X | ||||
| Cash Flow From Operations | (69.77 M) | ||||
| Short Ratio | 11.29 X | ||||
| Earnings Per Share | (1.88) X | ||||
| Price To Earnings To Growth | 0.28 X | ||||
| Target Price | 37.88 | ||||
| Number Of Employees | 60 | ||||
| Beta | 1.07 | ||||
| Market Capitalization | 1.68 B | ||||
| Total Asset | 363.56 M | ||||
| Retained Earnings | (251.31 M) | ||||
| Working Capital | 332.87 M | ||||
| Net Asset | 363.56 M |
About Tyra Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tyra Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tyra Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tyra Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Tyra Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tyra Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tyra Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tyra Biosciences Stock:Check out Tyra Biosciences Piotroski F Score and Tyra Biosciences Altman Z Score analysis. For information on how to trade Tyra Stock refer to our How to Trade Tyra Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tyra Biosciences. If investors know Tyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Tyra Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Tyra Biosciences requires distinguishing between market price and book value, where the latter reflects Tyra's accounting equity. The concept of intrinsic value—what Tyra Biosciences' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Tyra Biosciences' price substantially above or below its fundamental value.
Please note, there is a significant difference between Tyra Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tyra Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Tyra Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.